Overview

A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC

Status:
Active, not recruiting

Trial end date:
2021-12-31

Target enrollment:

Participant gender:

Summary

Similar clinical trial results demonstrated that anti-PD-1 antibodies prolonged OS to approximately 9 months compared with 6 months in docetaxel group. Anti-PD-1 therapy in Chinese squamous NSCLC patients will be investigated in this clinical trial. Additionally the correlation between PD-L1 expression and the response to IBI308 treatment in Chinese squamous cell NSCLC as well as the role of irRECIST in immune checkpoint inhibitor treatment evaluation will also be assessed

Phase:

Phase 3

Details

Lead Sponsor:

Innovent Biologics (Suzhou) Co. Ltd.

Treatments:

Docetaxel